HKHanna Koskinen

Hanna Koskinen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hanna Koskinen has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cancer medicines assessment and funding in Finland: contextual judgement and institutional boundaries in a multi-channel system

    by Onni Kärkkäjärvi, Anna-Maria Ruuskanen, Anna-Riia Holmström, Katariina Klintrup, Kati Sarnola, Hanna Koskinen, Terhi Kurko

  • Open Access

    Long-Term Proton Pump Inhibitor Therapy Is Common Among Older Adults: An 8-Year Finnish Nationwide Register Study

    by Leeni Minkkinen, Heini Kari, Fredriikka Nurminen, Juho Leppänen, Hanna Koskinen

  • Open Access

    Attitudes and Perceptions Towards Advanced Automation in the Nuclear Domain

    by Jari Laarni, Satu Pakarinen, Tomi Passi, Kristian Lukander, Hanna Koskinen, Marja Liinasuo

    This study examined the attitudes and perceptions of main control room (MCR) operators at a Finnish Evolutionary Power Reactor (EPR) nuclear power plant (NPP) towards advanced automation systems a few years after the plant’s commissioning. The analysis draws on group and individual interviews and on results from the revised Automation-Induced Complacency Potential Scale (AICP-R). The interview themes were based on a conceptual model of the association between automation features and automation attitudes and perceptions. Seven operating crews, 28 operators in total, participated in the interview sessions. The respondents viewed advanced automation as essential to plant operation but emphasised the need for human supervision, especially during failures. They generally trusted automation in routine tasks but monitored it closely and were prepared to intervene manually when necessary. The complexity of automation systems and the possibility of failures underline the importance of training, clear procedures, and close collaboration with maintenance personnel. The findings suggest that attitudes towards automation evolve with experience and with improvements in system reliability and operator competence.

  • Open Access

    Real-Life Use Patterns of Androgen Receptor Pathway Inhibitors (ARPIs): A Nationwide Register-Based Study in Finland During 2012–2023

    by Terhi Kurko, Pekka Heino, Pirkko-Liisa Kellokumpu-Lehtinen, Kati Sarnola, Hanna Koskinen, Maarit Bärlund

    Background and Objective: Prostate cancer (PC) is the most common cancer among males in the Western World. Androgens are key growth regulators both in normal and malignant prostate growth. Several new types of androgen pathway inhibitors (ARPIs) have been developed for the treatment of PC. Despite the lack of evidence, sequential use of ARPIs has been adopted into everyday clinical practice. This study aimed to assess real-life ARPI use patterns, especially sequential use and treatment costs, in Finland. Methods: Nationwide register data on all ARPI (enzalutamide, apalutamide, darolutamide, abiraterone) purchases recorded in the National Health Insurance scheme register maintained by the Social Insurance Institution of Finland from January 2012 to December 2023 were used. The data included patient demographics and medicine purchase details, which were descriptively analysed. Results: During the study period, 8369 patients initiated ARPIs. The median age of the users was 75.1 years. Of these, 32.1% (n = 2685) used at least two ARPIs sequentially. The proportion of treatment initiations leading to sequential use increased from 36% in 2012 to 56% in 2017, then decreased to 14% in 2022. The total cost of sequential use was €43.8 million. Limitations include the unrecorded phase of PC. The study’s strength is its inclusion of all reimbursed ARPI purchases nationwide. Conclusions: Despite the lack of evidence, sequential ARPI use was initially prevalent but declined after the introduction of new guidelines. Randomised trials are needed to guide the sequential use of these medicines. Patient summary: Androgen pathway inhibitors (ARPIs) are widely used in prostate cancer in Finland. One-third of patients use at least two ARPIs sequentially to inhibit testosterone effect. However, there are no large clinical trials published demonstrating the benefits of sequential treatment. More evidence is needed to justify sequential use.

  • Open Access

    New cancer medicines in Europe 2010–2020: comparison of medicines with or without extensions of indications

    by Anna-Maria Ruuskanen, Terhi Kurko, Kati Sarnola, Katariina Klintrup, Hanna Koskinen

    Introduction During the last decade, extensions of therapeutic indications have been one of the most common methods to extend the lifecycle of a medical product in the post-authorisation phase and to increase the use and sales of medicines. The aim of this study was to gain understanding of the lifecycle of cancer medicines and especially the role and level of evidence extensions in comparison to first indications. Materials and methods We identified all new outpatient cancer medicines approved by the European Medicines Agency between 2010 and 2020 and the extensions to their indications. We compared general study design characteristics from the European public assessment reports using critical appraisal tools and clinical added value assessments. Results We identified altogether 55 new outpatient cancer medicines, 31 of which had one or more extension(s) of indication and 24 had no extension of indication. In total, there were 57 extensions. The most common extension of indication was a change in the treatment line (35%). Compared with first indications, the overall quality of studies supporting extensions was better in terms of study designs. The proportion of medicines providing CAV was higher in extensions compared with first indication of medicines with and without extensions. Conclusions Based on different assessments and perspectives, we found that extensions of indications are a very common and important part of extending the lifecycle of outpatient cancer medicines in Europe. Our findings also suggest that the clinical value of cancer medicines increases with extensions.


  • Open Access

    Time Series Analysis on the Impact of Generic Substitution and Reference Pricing on Antipsychotic Costs in Finland

    by Hanna Koskinen, Hennamari Mikkola, Leena K. Saastamoinen, Elina Ahola, Jaana E. Martikainen


  • Open Access

    The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic medication in Finland

    by Hanna Koskinen, Elina Ahola, Leena K Saastamoinen, Hennamari Mikkola, Jaana E Martikainen

    To assess the impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic drugs in Finland during the first year after its launch. Furthermore, the additional impact of reference pricing on prior implemented generic substitution is assessed. A retrospective analysis was performed between 2006 and 2010. A segmented linear regression analysis of interrupted time series was used to estimate changes in the levels and trends in the cost of one day of treatment. Of the study drugs, clozapine belonged to generic substitution already at the start of the study period while olanzapine and quetiapine were included in generic substitution alongside with reference pricing in 2009. Risperidone was included in generic substitution in 2008, before reference pricing. A substantial decrease in the daily cost of all four antipsychotic substances was seen after one year of the implementation of reference pricing and the extension of generic substitution. The impact ranged from -29.9% to -66.3%, and it was most substantial on the daily cost of olanzapine. Also in the daily cost of risperidone a substantial decrease of -43.3% was observed. However, most of these savings, -32.6%, were generated by generic substitution which had been adopted prior. Reference pricing and the extension of generic substitution produced substantial savings on antipsychotic medication costs during the first year after its launch, but the intensity of the impact differed between active substances. Furthermore, our results suggest that the additional cost savings from reference pricing after prior implemented generic substitution, are comparatively low.


  • Cost-effectiveness of implementing national guidelines in the treatment of acute otitis media in children

    by Hanna Koskinen, Ulla-Maija Rautakorpi, Harri Sintonen, Pekka Honkanen, Solja Huikko, Pentti Huovinen, Timo Klaukka, Erkki Palva, Risto P. Roine, Hannu Sarkkinen, et al.

    Objectives: Acute otitis media (AOM) is one of the most common diseases of childhood, representing a major disease burden on the society. New evidence-based guidelines for AOM, focusing on children under 7 years of age, were introduced in Finland in 1999. The aim of this study was to evaluate the cost-effectiveness of implementing those guidelines in Finland.Methods: A 5-year prospective trial was conducted in thirty community primary healthcare centers in Finland. All AOM patients between 0 and 6 years of age visiting the study health centers for the first time, for this episode of illness, during 1 week in November 1998 (n = 579) and November 2002 (n = 369) were included in this study. The outcome measure was the percentage of symptom-free patients.Results: The mean direct cost of an AOM episode per patient stayed almost the same after implementing the guidelines, €152 in 1998 and €150 in 2002. After implementing the guidelines, the percentage of symptom-free patients was 10 percentage points higher than before the guidelines. The treatment after the implementation of the guidelines, thus, was a dominant strategy.Conclusions: Implementing the guidelines to the treatment of AOM in children was associated with extra health benefits at slightly lower direct costs and, thus, is a dominant strategy. The focus of this study was on the short-term effects of the treatment; including long-term effects in the analysis might affect the results.